India's Medical Device Market Decoded: 4,108 Manufacturers, 62% Imports
India's medical device market reached $20.98B in 2026 with 4,108 licensed manufacturers. Class A and B devices dominate at 76%, while imports supply 62% of market demand.
Executive Summary
India is the fourth-largest medical device market in Asia and one of the fastest-growing globally. The market reached an estimated $20.98 billion in 2026 and is projected to grow to $38.08 billion by 2030, driven by expanding healthcare infrastructure, rising chronic disease burden, and increasing access to advanced medical technologies.
Yet beneath the growth narrative lies a market that is structurally dependent on imports. 62% of India's medical device demand is met by imports, with the United States, Germany, and China as the top three source countries. Only 38% is supplied by domestic production — and India's domestic strength is concentrated in low-risk categories like syringes, consumables, and simple disposables. For cardiology, oncology, and high-end imaging, the country remains almost entirely import-dependent.
On the regulatory side, the Central Drugs Standard Control Organization (CDSCO) has significantly expanded its oversight. As of March 2026, 4,108 medical device manufacturers are licensed in India, distributed across risk classes as follows:
| Class | Risk Level | Licensed Manufacturers |
|---|---|---|
| Class A | Low | 2,099 |
| Class B | Low-to-moderate | 2,560 |
| Class C | Moderate-to-high | 1,123 |
| Class D | High | 343 |
(Note: Some manufacturers hold licenses across multiple classes, so the totals exceed 4,108.)
This article breaks down India's device class distribution, market segmentation, import dependency, licensing landscape, and the regulatory developments shaping the market in 2026 and beyond.
Data Source and Methodology
This analysis draws on multiple publicly available sources:
Manufacturer licensing data from the Press Information Bureau of India (PIB), Ministry of Chemicals and Fertilizers, reported March 2026.
Market sizing and import/domestic split from industry reports citing CDSCO disclosures and Pharmexcil data (FY 2025–26).
Risk classification distribution from CDSCO's Medical Devices Rules, 2017 (MDR 2017) framework and published classification lists.
Fee schedules and regulatory timelines from CDSCO public guidance documents and SUGAM portal disclosures.
Market segment data from industry analyses of the Indian medical device market (FY 2025–26).
Where statistics are derived from CDSCO's published data or government disclosures, this is noted. All figures reflect the most current publicly available data as of June 2026.
Risk Classification Framework: Class A Through D
India classifies medical devices into four risk tiers under the Medical Devices Rules, 2017, following the Global Harmonization Task Force (GHTF) model:
| Class | Risk Level | Examples | Licensing Authority |
|---|---|---|---|
| Class A | Low | Surgical dressings, tongue depressors, exam gloves | State Licensing Authority |
| Class B | Low-to-moderate | Hypodermic needles, BP monitors, suction equipment | State Licensing Authority |
| Class C | Moderate-to-high | Ventilators, infusion pumps, dialysis equipment | CDSCO Central |
| Class D | High | Heart valves, implantable defibrillators, HIV IVD reagents | CDSCO Central |
The distribution of classified device types across the four tiers is approximately:
| Class | Share of Classified Devices |
|---|---|
| Class A | 42% |
| Class B | 34% |
| Class C | 17% |
| Class D | 7% |
This pyramid shape — heavily weighted toward lower-risk devices — mirrors the global pattern. Class A and B together account for 76% of classified device types, while the high-risk Class D represents only 7%.
Licensing by Risk Class
The 4,108 licensed manufacturers distribute unevenly across risk classes:
| Class | Manufacturers | % of Total Licenses |
|---|---|---|
| Class A | 2,099 | 51.1% |
| Class B | 2,560 | 62.3% |
| Class C | 1,123 | 27.3% |
| Class D | 343 | 8.3% |
Class B has the most licensees (2,560), slightly exceeding Class A (2,099). This is notable because Class B devices require more documentation and quality oversight than Class A, yet the manufacturing base is broadly distributed — suggesting a competitive, fragmented market in the low-to-moderate risk segment.
Class D manufacturers are scarce (343), reflecting the high barriers to entry for high-risk device manufacturing in India. These 343 firms represent the domestic capability for implantable defibrillators, heart valves, and other critical devices — but much of India's Class D demand is met through imports.
Market Segmentation: Where the Money Goes
India's medical device market breaks down by product category as follows (FY 2025–26):
| Segment | Market Share |
|---|---|
| Diagnostic Imaging | 22% |
| Consumables and Disposables | 19% |
| Patient Aids | 14% |
| IVD/Reagents | 14% |
| Orthopedic and Prosthetic | 12% |
| Cardiology | 10% |
| Others | 5% |
| Other therapeutic devices | 4% |
Diagnostic imaging is the largest single segment at 22%, driven by demand for CT, MRI, ultrasound, and X-ray systems — nearly all of which are imported. Consumables and disposables (19%) is the segment where India's domestic manufacturing is strongest, with domestic producers like HLL Lifecare, Romsons, and polyMedica supplying a significant share of syringes, catheters, and surgical consumables.
Cardiology (10%) and orthopedic/prosthetic (12%) together represent over a fifth of the market, but both segments are heavily import-dependent. India's domestic capability in cardiac stents has grown (with firms like Meril Life Sciences gaining market share), but pacemakers, artificial heart valves, and advanced orthopedic implants remain primarily imported.
The Import Dependency: 62% Foreign-Sourced
India's medical device import dependency is the defining structural feature of the market:
| Source | Share (FY 2025–26) |
|---|---|
| Imports | 62% |
| Domestic Production | 38% |
This 62% import share reflects the overall market including consumables and disposables where India is competitive. For high-end and technologically advanced devices specifically, the import dependency is substantially higher — industry estimates place it at 70–80% for advanced imaging, cardiac implants, and oncology devices. India's medical device exports reached $4.1 billion in FY25, but imports were $8.6 billion, resulting in a trade deficit that underscores the structural import dependency.
The top source countries for medical device imports are:
United States — the largest single source, led by imaging systems, cardiovascular devices, and surgical instruments
Germany — strong in diagnostic equipment, orthopedic implants, and hospital infrastructure
China — dominates consumables, protective equipment, and lower-cost device components
Singapore — serves as a regional distribution hub for multinational manufacturers
Japan — supplies advanced imaging, endoscopy, and precision instruments
Netherlands — a European distribution hub, particularly for Philips and other EU-based manufacturers
This import dependency is not uniform across device classes:
Low-risk (Class A/B): India has substantial domestic capability in syringes, gloves, surgical dressings, and basic disposables. These categories have the highest domestic content ratio.
Mid-risk (Class C): Partially import-dependent. India has growing capability in patient monitors, basic imaging, and some therapeutic devices, but advanced Class C products (e.g., high-end ventilators, MRI systems) are mostly imported.
High-risk (Class D): Almost entirely import-dependent. Cardiac implants, neurological devices, and advanced IVD reagents are sourced predominantly from US, EU, and Japanese manufacturers.
The import license (MD-15) volumes consistently outstrip manufacturing license (MD-5/MD-9) volumes at CDSCO each fiscal year, reflecting this structural dependency.
CDSCO Regulatory Framework: Key Fee Structures
CDSCO's fee schedule for medical device licensing, effective under MDR 2017:
| Activity | Class A | Class B | Class C | Class D |
|---|---|---|---|---|
| Manufacturing Site Fee (MD-5/MD-9) | ₹5,000 | ₹5,000 | ₹50,000 | ₹50,000 |
| Manufacturing Per-Device Fee | ₹500 | ₹500 | ₹1,000 | ₹1,000 |
| Import Site Fee (MD-15) | $1,000 | $2,000 | $3,000 | $3,000 |
| Import Per-Device Fee | $50 | $1,000 | $1,500 | $1,500 |
For foreign manufacturers, the cost of importing a Class C or D device into India is substantial — $3,000 site fee plus $1,500 per device — creating a meaningful barrier to market entry for smaller foreign firms.
Regulatory Timelines
| Class | Filing Authority | Typical End-to-End Timeline |
|---|---|---|
| Class A (non-sterile, non-measuring) | Online registration only | Near-immediate |
| Class A (sterile/measuring) and Class B | State Licensing Authority | 3–4 months |
| Class C and D (no clinical study) | CDSCO Central | 6–9 months |
| Class C and D (novel device, PMCI required) | CDSCO Central | 12–18 months |
For novel Class C/D devices not previously approved in a CDSCO-recognized reference jurisdiction (US, EU, UK, Japan, Canada, Australia), CDSCO can require a Pre-Market Clinical Investigation (PMCI) on Indian patients, adding 6–12 months to the timeline.
Recent CDSCO Regulatory Developments (2025–2026)
Expanded Risk Classification Lists
CDSCO has been actively publishing risk classification lists by clinical specialty:
Oncology (January 2026): 77 classified devices, including 23 newly added types such as AI-powered cancer detection software (classified as Class C)
Radiotherapy (November 2025): 119 classified devices
Interventional Radiology (November 2025): 187 classified devices
Class A non-sterile/non-measuring (October 2025): Updated classification list in effect
Software as a Medical Device (SaMD)
CDSCO listed a final Guidance Document on Medical Device Software (CDSCO/MD/GD/MDSW/01/2026) on 21 July 2026. It is a map of existing MDR-2017 practice for MDSW, not a new software statute. Use that operating manual for qualification, Table 2 classification, NSWS versus cdscomdonline routing, and optional Algorithm Change Protocol. Do not treat the 2024 draft-SaMD language on the country 101 page as current law.
Outsourced Sterilization Labels and Ninth Schedule Fees (G.S.R. 743(E))
MoHFW notified G.S.R. 743(E) on 14 August 2026 (gazetted 19 August 2026): Rule 44(p) sterilization-site licence numbers on outsourced-sterilization labels become mandatory on 14 February 2027, and the Ninth Schedule sets government laboratory test/evaluation fees under Rules 19 and 69. Same-day G.S.R. 744(E) is a different instrument. This census page does not own that labelling or fee map.
Post-Market Surveillance Strengthening
CDSCO has enhanced post-market surveillance enforcement in 2025–26, with increased focus on:
Periodic Safety Update Reports (PSURs)
Field Safety Corrective Action (FSCA) compliance for Class C and D licensees
Stricter inspection coordination between central and state authorities
BIS Technical Regulation
The Bureau of Indian Standards (BIS) Scheme X certification deadline has been extended to September 1, 2026. Medical devices within the notified BIS scope must meet Indian Standards (IS) by that date or risk losing market access.
PLI Scheme and Domestic Manufacturing Push
The Indian government launched a ₹500 crore (~$59 million) Production Linked Incentive (PLI) scheme to boost domestic medical device manufacturing, with a total scheme outlay of ₹3,420 crore. The initiative offers:
Capital subsidies for manufacturing key components
Clinical research support
Common infrastructure development
Industry promotion
As of December 2025, 24 greenfield projects have been commissioned under the PLI scheme, with production started for 57 products including high-end devices on which India was previously import-dependent — linear accelerators, MRI systems, ultrasound, CT scans, mammograms, C-arm units, and X-ray machines. Cumulative eligible sales under the scheme reached ₹13,624.52 crore ($1.56 billion), including export sales worth ₹6,425.48 crore ($740 million).
Additionally, the Uttar Pradesh Medical Device Park at Sector 28, YEIDA, with an approved cost of ₹439.49 crore (~$47 million), has attracted investment interest from Wipro GE, Philips, Siemens, and Panacea.
What This Means for Industry
India is a high-growth market with structural import dependency. The $20.98B market growing toward $38B by 2030 represents significant opportunity, but 62% of demand is met by imports. For foreign manufacturers, this means India is not just an export destination — it is the primary supply source for most advanced device categories.
Regulatory maturity is increasing. CDSCO's expanded classification lists, SaMD guidance, and post-market surveillance strengthening signal a regulator that is aligning with global standards. Manufacturers should expect increasing scrutiny, particularly for Class C and D devices.
Domestic manufacturing incentives create competitive dynamics. The PLI scheme and medical device parks are designed to reduce import dependency. Foreign manufacturers should consider whether local manufacturing partnerships or wholly-owned subsidiaries in India could serve both the domestic and regional markets.
The Class A/B space is crowded and competitive. With 2,099 and 2,560 licensed manufacturers respectively, the low-risk device segment is fragmented. New entrants should expect intense price competition from established domestic producers.
Class D remains a concentrated opportunity. Only 343 licensed manufacturers for high-risk devices, combined with near-total import dependency, means the addressable market for Class D devices is large and underserved by domestic production.
Data sources: Press Information Bureau of India (PIB), Ministry of Chemicals and Fertilizers (March 2026); CDSCO Medical Devices Rules, 2017; Pharmexcil and industry market reports (FY 2025–26); CDSCO SUGAM portal disclosures; Bureau of Indian Standards (BIS) notifications. Analysis by MedDeviceGuide. Market sizing figures are estimates from industry reports and should be treated as approximate. Fee schedules are from CDSCO published guidance and may be subject to change.